954 related articles for article (PubMed ID: 19118660)
21. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
22. Osteoclast lineage and function.
Väänänen HK; Laitala-Leinonen T
Arch Biochem Biophys; 2008 May; 473(2):132-8. PubMed ID: 18424258
[TBL] [Abstract][Full Text] [Related]
23. Human osteoblasts produce cathepsin K.
Mandelin J; Hukkanen M; Li TF; Korhonen M; Liljeström M; Sillat T; Hanemaaijer R; Salo J; Santavirta S; Konttinen YT
Bone; 2006 Jun; 38(6):769-77. PubMed ID: 16337236
[TBL] [Abstract][Full Text] [Related]
24. Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis.
Knowles HJ; Athanasou NA
J Pathol; 2009 Jun; 218(2):256-64. PubMed ID: 19291710
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity.
Martin TJ; Ng KW
J Cell Biochem; 1994 Nov; 56(3):357-66. PubMed ID: 7876329
[TBL] [Abstract][Full Text] [Related]
26. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
27. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
28. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts.
Vääräniemi J; Halleen JM; Kaarlonen K; Ylipahkala H; Alatalo SL; Andersson G; Kaija H; Vihko P; Väänänen HK
J Bone Miner Res; 2004 Sep; 19(9):1432-40. PubMed ID: 15312243
[TBL] [Abstract][Full Text] [Related]
29. Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1.
Riihonen R; Nielsen S; Väänänen HK; Laitala-Leinonen T; Kwon TH
Matrix Biol; 2010 May; 29(4):287-94. PubMed ID: 20079835
[TBL] [Abstract][Full Text] [Related]
30. Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA.
Selinger CI; Day CJ; Morrison NA
J Cell Biochem; 2005 Dec; 96(5):996-1002. PubMed ID: 16149069
[TBL] [Abstract][Full Text] [Related]
31. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
32. Osteoclast-osteoblast communication.
Matsuo K; Irie N
Arch Biochem Biophys; 2008 May; 473(2):201-9. PubMed ID: 18406338
[TBL] [Abstract][Full Text] [Related]
33. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
34. Localisation and activity of cathepsins K and B in equine osteoclasts.
Gray AW; Davies ME; Jeffcott LB
Res Vet Sci; 2002 Apr; 72(2):95-103. PubMed ID: 12027589
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the ultrastructural assessment of osteoclastic resorptive functions.
Sasaki T
Microsc Res Tech; 1996 Feb; 33(2):182-91. PubMed ID: 8845517
[TBL] [Abstract][Full Text] [Related]
36. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
37. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix.
Lutter AH; Hempel U; Wolf-Brandstetter C; Garbe AI; Goettsch C; Hofbauer LC; Jessberger R; Dieter P
J Cell Biochem; 2010 Apr; 109(5):1025-32. PubMed ID: 20108253
[TBL] [Abstract][Full Text] [Related]
38. High dose glucocorticoid hampers bone formation and resorption after bone marrow ablation in rat.
Kondo N; Tokunaga K; Ito T; Arai K; Amizuka N; Minqi L; Kitahara H; Ito M; Naito M; Shu-Ying J; Oda K; Murai T; Takano R; Ogose A; Endo N
Microsc Res Tech; 2006 Oct; 69(10):839-46. PubMed ID: 16972225
[TBL] [Abstract][Full Text] [Related]
39. Concanavalin A directly stimulates bone-resorbing activity of osteoclasts and their gene expression of cathepsin K/OC-2.
Kakudo S; Mano H; Shiokawa M; Mori Y; Kumegawa M; Hakeda Y
Biochem Biophys Res Commun; 1997 May; 234(3):600-4. PubMed ID: 9175759
[TBL] [Abstract][Full Text] [Related]
40. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
